Clinical Trials Directory
We are doing this study to compare the early treatment (before you have cancer symptoms) of Venetoclax and Obitnutuzumab (V-O) to the usual treatment of V-O after you have cancer symptoms. This study will help doctors figure out if early treatment is better, the same, or worse than the usual approach of waiting until the patient has cancer symptoms before starting treatment.
We are doing this study to find out if a pair of investigational drugs called ramucirumab and pembrolizumab (the study drugs) are a safe and effective treatment for your form of cancer. We want to know how well the study drugs work in comparison to the standard treatment for Stage IV or recurrent NSCLC.
We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.
We are doing this study to find out the highest dose of a drug called olaparib that is safe to give at
the same time as stereotactic radiosurgery (SRS). We also want to see if we can lessen the chance of having your cancer return by following the olaparib + SRS treatment with a combination of chemotherapy and a drug called durvalumab.
We are doing this study to find out if an investigational drug called XL092 (the study drug) is a safe and effective option on its own or in combination with other anticancer drugs.
We are doing this study to find out if an experimental drug called RO7589831 (the study drug) is a safe and effective option for cancers with solid tumors. We also want to find out what the best dose of the study drug is in this study.
We are doing this study to figure out how well an investigational drug called CGT9486 (the study drug - also known as bezuclastinib) works in people who are diagnosed with a type of Nonadvanced Systemic Mastocytosis (NonAdvSM). These types are either Indolent Systemic Mastocytosis (ISM) or Smoldering Systemic Mastocytosis (SSM).
We are doing this study to find out how much skin should be removed from around a melanoma to lower the chances of the melanoma coming back. We don't have enough evidence to know exactly how much skin to remove around the melanoma to give people the best chance at a good outcome.